FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2158834148> ?p ?o ?g. }

• W2158834148 endingPage "280" @default.
• W2158834148 startingPage "273" @default.
• W2158834148 abstract "Background It has been demonstrated that the occurrence of ischemic stroke is more prevalent in AF patients, when increased levels of inflammatory markers are present. Objective The aim of this study was to evaluate the effect of intensive cholesterol lowering therapy on inflammatory markers and evidence of thrombotic in elderly AF patients treated with OAC. Methods 34 elderly patients (69–85 yrs) were randomized to double blind treatment with atorvastatin 40 mg plus ezetimibe 10 mg (n = 17) or double placebo (n = 17) for one year. All were anticoagulated with warfarin (target INR 2.5–3.5). Every 3 months inflammatory markers and parameters for evaluation of haemostatic and fibrinolytic activity were measured. Results Anti-inflammatory effects in the treatment arm were reflected by a significant decrease from baseline in hs-CRP, FGF, G-CSF, GM-CSF, IL-1ra, IL-9, IL-13, IL-17 and interferon-γ (P < .05). There was no significant decrease in the control group. Endogenous thrombin potential was still present and active but decreased during treatment (P = .0005) compared to the placebo group. After 12 months treatment, a significant correlation was found between changes in endogenous thrombin potential and hs-CRP, interferon-γ and G-CSF, respectively. No hemorrhagic complications occurred. Conclusion Intensive cholesterol lowering significantly reduced inflammation and was accompanied by reduced thrombin generation. Larger clinical studies should determine which inflammatory markers are most specific and sensitive for estimating the inflammatory burden in these patients and at which corresponding thrombin activity level it is beneficial and safe to add intensive cholesterol lowering therapy even if normal cholesterol levels are present. It has been demonstrated that the occurrence of ischemic stroke is more prevalent in AF patients, when increased levels of inflammatory markers are present. The aim of this study was to evaluate the effect of intensive cholesterol lowering therapy on inflammatory markers and evidence of thrombotic in elderly AF patients treated with OAC. 34 elderly patients (69–85 yrs) were randomized to double blind treatment with atorvastatin 40 mg plus ezetimibe 10 mg (n = 17) or double placebo (n = 17) for one year. All were anticoagulated with warfarin (target INR 2.5–3.5). Every 3 months inflammatory markers and parameters for evaluation of haemostatic and fibrinolytic activity were measured. Anti-inflammatory effects in the treatment arm were reflected by a significant decrease from baseline in hs-CRP, FGF, G-CSF, GM-CSF, IL-1ra, IL-9, IL-13, IL-17 and interferon-γ (P < .05). There was no significant decrease in the control group. Endogenous thrombin potential was still present and active but decreased during treatment (P = .0005) compared to the placebo group. After 12 months treatment, a significant correlation was found between changes in endogenous thrombin potential and hs-CRP, interferon-γ and G-CSF, respectively. No hemorrhagic complications occurred. Intensive cholesterol lowering significantly reduced inflammation and was accompanied by reduced thrombin generation. Larger clinical studies should determine which inflammatory markers are most specific and sensitive for estimating the inflammatory burden in these patients and at which corresponding thrombin activity level it is beneficial and safe to add intensive cholesterol lowering therapy even if normal cholesterol levels are present." @default.
• W2158834148 created "2016-06-24" @default.
• W2158834148 creator A5006886393 @default.
• W2158834148 creator A5009140185 @default.
• W2158834148 creator A5026747664 @default.
• W2158834148 creator A5029050597 @default.
• W2158834148 creator A5034439136 @default.
• W2158834148 creator A5063563504 @default.
• W2158834148 creator A5065978967 @default.
• W2158834148 creator A5079150092 @default.
• W2158834148 creator A5080162215 @default.
• W2158834148 creator A5085526211 @default.
• W2158834148 creator A5089644471 @default.
• W2158834148 date "2011-07-01" @default.
• W2158834148 modified "2023-09-25" @default.
• W2158834148 title "Persisting thrombin activity in elderly patients with atrial fibrillation on oral anticoagulation is decreased by anti-inflammatory therapy with intensive cholesterol-lowering treatment" @default.
• W2158834148 cites W1546258268 @default.
• W2158834148 cites W1979898865 @default.
• W2158834148 cites W1986746098 @default.
• W2158834148 cites W1992084132 @default.
• W2158834148 cites W2000172311 @default.
• W2158834148 cites W2024581697 @default.
• W2158834148 cites W2025247505 @default.
• W2158834148 cites W2037251934 @default.
• W2158834148 cites W2037349803 @default.
• W2158834148 cites W2039089847 @default.
• W2158834148 cites W2045307970 @default.
• W2158834148 cites W2046514727 @default.
• W2158834148 cites W2048154508 @default.
• W2158834148 cites W2050695893 @default.
• W2158834148 cites W2055586130 @default.
• W2158834148 cites W2058711306 @default.
• W2158834148 cites W2066267661 @default.
• W2158834148 cites W2074613224 @default.
• W2158834148 cites W2103751952 @default.
• W2158834148 cites W2106384954 @default.
• W2158834148 cites W2107714800 @default.
• W2158834148 cites W2120289695 @default.
• W2158834148 cites W2120386224 @default.
• W2158834148 cites W2120795994 @default.
• W2158834148 cites W2125044993 @default.
• W2158834148 cites W2125912540 @default.
• W2158834148 cites W2132505348 @default.
• W2158834148 cites W2150576478 @default.
• W2158834148 cites W2151074096 @default.
• W2158834148 cites W2154863934 @default.
• W2158834148 cites W2159730165 @default.
• W2158834148 cites W2164698528 @default.
• W2158834148 cites W2167574024 @default.
• W2158834148 cites W2775834309 @default.
• W2158834148 doi "https://doi.org/10.1016/j.jacl.2011.05.003" @default.
• W2158834148 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21784372" @default.
• W2158834148 hasPublicationYear "2011" @default.
• W2158834148 type Work @default.
• W2158834148 sameAs 2158834148 @default.
• W2158834148 citedByCount "18" @default.
• W2158834148 countsByYear W21588341482012 @default.
• W2158834148 countsByYear W21588341482013 @default.
• W2158834148 countsByYear W21588341482014 @default.
• W2158834148 countsByYear W21588341482015 @default.
• W2158834148 countsByYear W21588341482016 @default.
• W2158834148 countsByYear W21588341482017 @default.
• W2158834148 countsByYear W21588341482018 @default.
• W2158834148 countsByYear W21588341482019 @default.
• W2158834148 countsByYear W21588341482020 @default.
• W2158834148 countsByYear W21588341482021 @default.
• W2158834148 countsByYear W21588341482022 @default.
• W2158834148 countsByYear W21588341482023 @default.
• W2158834148 crossrefType "journal-article" @default.
• W2158834148 hasAuthorship W2158834148A5006886393 @default.
• W2158834148 hasAuthorship W2158834148A5009140185 @default.
• W2158834148 hasAuthorship W2158834148A5026747664 @default.
• W2158834148 hasAuthorship W2158834148A5029050597 @default.
• W2158834148 hasAuthorship W2158834148A5034439136 @default.
• W2158834148 hasAuthorship W2158834148A5063563504 @default.
• W2158834148 hasAuthorship W2158834148A5065978967 @default.
• W2158834148 hasAuthorship W2158834148A5079150092 @default.
• W2158834148 hasAuthorship W2158834148A5080162215 @default.
• W2158834148 hasAuthorship W2158834148A5085526211 @default.
• W2158834148 hasAuthorship W2158834148A5089644471 @default.
• W2158834148 hasConcept C126322002 @default.
• W2158834148 hasConcept C142724271 @default.
• W2158834148 hasConcept C168563851 @default.
• W2158834148 hasConcept C201267052 @default.
• W2158834148 hasConcept C204787440 @default.
• W2158834148 hasConcept C27081682 @default.
• W2158834148 hasConcept C2776301958 @default.
• W2158834148 hasConcept C2776914184 @default.
• W2158834148 hasConcept C2777292125 @default.
• W2158834148 hasConcept C2777482532 @default.
• W2158834148 hasConcept C2778163477 @default.
• W2158834148 hasConcept C2778657065 @default.
• W2158834148 hasConcept C2779161974 @default.
• W2158834148 hasConcept C57002609 @default.
• W2158834148 hasConcept C71924100 @default.
• W2158834148 hasConcept C89560881 @default.
• W2158834148 hasConcept C90924648 @default.
• W2158834148 hasConceptScore W2158834148C126322002 @default.

• next